SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced the publication of an analysis highlighting that Bladder EpiCheck® can reduce both patient burden and healthcare system costs in the U.S. and European countries for low grade intermediate risk non-muscle invasive bladder cancer (NMIBC). The analysis, titled “Alternating Cystoscopy with Bladder EpiCheck® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model,” was published in the peer-reviewed journal Bladder Cancer.
Go to the inbox of the email
address you just used to sign up.
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “firstname.lastname@example.org”.
Click on the link inside the <br>email and you’re good to go.